Pediatrix Medical Group (NYSE:MD) Lowered to Hold Rating by StockNews.com

Pediatrix Medical Group (NYSE:MD - Get Free Report) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Thursday.

Several other brokerages have also recently commented on MD. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Mizuho increased their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research note on Tuesday. Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. UBS Group raised their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Finally, Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a report on Monday, November 4th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $16.10.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock traded up $0.26 on Thursday, reaching $14.75. The company's stock had a trading volume of 531,265 shares, compared to its average volume of 864,097. The stock has a 50-day moving average price of $12.84 and a 200-day moving average price of $10.00. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $16.41. The company has a market capitalization of $1.27 billion, a P/E ratio of -4.82, a PEG ratio of 2.08 and a beta of 1.55. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. During the same quarter in the prior year, the firm earned $0.29 EPS. Pediatrix Medical Group's quarterly revenue was up .9% on a year-over-year basis. Analysts expect that Pediatrix Medical Group will post 1.26 EPS for the current year.

Insider Buying and Selling

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares of the company's stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now directly owns 138,683 shares of the company's stock, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 53,808 shares of company stock valued at $751,277. 2.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors have recently modified their holdings of MD. Rubric Capital Management LP boosted its stake in Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock worth $61,532,000 after purchasing an additional 7,241,400 shares during the period. Dana Investment Advisors Inc. lifted its holdings in shares of Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock valued at $7,725,000 after purchasing an additional 455,785 shares during the last quarter. Boston Partners increased its position in shares of Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company's stock valued at $17,702,000 after acquiring an additional 453,254 shares in the last quarter. Weiss Asset Management LP raised its holdings in shares of Pediatrix Medical Group by 50.5% during the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company's stock valued at $10,580,000 after purchasing an additional 306,143 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company's stock valued at $2,192,000 after buying an additional 251,072 shares during the period. 97.71% of the stock is owned by institutional investors and hedge funds.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.